What These Ratios Tell Us About AstraZeneca plc

AstraZeneca plc (LON:AZN) remains a serious income play, says Roland Head, but near-term growth is unlikely.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Before I decide whether to buy a company’s shares, I always like to look at two core financial ratios — return on equity and net gearing.

These two ratios provide an indication of how successful a company is at generating profits using shareholders’ funds and debt, and they have a strong influence on dividend payments and share price growth.

Today, I’m going to take a look at pharmaceutical firm AstraZeneca (LSE: AZN) (NYSE: AZN.US), to see how attractive it looks on these two measures.

Return on equity

The return a company generates on its shareholders’ funds is known as return on equity, or ROE. Return on equity can be calculated by dividing a company’s annual profit by its equity (ie, the difference between its total assets and its total liabilities) and is expressed as a percentage.

AstraZeneca’s share price has risen by 43% over the last five years, while its dividend has risen by 36%. However, the firm’s return on equity weakened last year, as its profits fell sharply:

AstraZeneca 2008 2009 2010 2011 2012 Average
ROE 39.8% 41.1% 36.7% 43.0% 26.8% 37.5%

What about debt?  

A key weakness of ROE is that it doesn’t show how much debt a company is using to boost its returns. My preferred way of measuring a company’s debt is by looking at its net gearing — the ratio of net debt to equity.

In the table below, I’ve listed Astra’s net gearing and ROE alongside those of its UK peers, Shire and GlaxoSmithKline:

Company Net gearing 5-year
average ROE
Shire -9.3%
(net cash)
24.7%
AstraZeneca 9.8% 37.5%
GlaxoSmithKline 230.1% 51.9%

Astra’s five-year average ROE looks impressive when set alongside its low gearing levels, which are a sharp contrast to Glaxo’s net debt of £15.4bn.

Is Astra a buy?

The only problem with Astra’s impressive past performance is that it isn’t going to be repeated — at least not for a few years.

City analysts expect Astra’s earnings to fall over the next couple of years, as it loses patent protection on several key products. At the same time, the firm will continue to spend on acquisitions to backfill its pipeline of new drugs.

For income seekers, Astra’s 5.7% dividend yield means that the firm must remain a contender. However, while the firm currently trades on a relatively low forward P/E of around 10, with earnings forecast to fall, the share price may follow, at least in the short term.

Overall, I rate Astra as a hold — long-term holders should do well, as should income seekers, but the firm’s sticky patch isn’t over yet.

Finding market-beating returns

Finding shares that can beat the market over a long period is hard, but if you already hold Astra’s stock, then you might be interested in learning about five star shares that have been identified by the Fool’s team of analysts as 5 Shares To Retire On.

I own three of the shares featured in this free report, and I don’t mind admitting they are amongst the most successful investments I’ve ever made.

To find out the identity of these five companies, click here to download your copy of this report now, while it’s still available.

> Roland owns shares in GlaxoSmithKline but does not own shares in any of the other companies mentioned in this article. The Motley Fool has recommended Shire.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Bearded man writing on notepad in front of computer
Investing Articles

Greggs’ share price tanked last week. So I bought more!

Could Greggs be one of the FTSE 250's best bargains following its share price slump? Royston Wild thinks so, as…

Read more »

Investing Articles

£10,000 invested in Games Workshop shares 5 years ago is now worth…

Despite inflation, higher interest rates, and a cost of living crisis, Games Workshop shares have gone from strength to strength…

Read more »

Investing Articles

How much in a Stocks and Shares ISA could earn me £500 of passive income each month?

Christopher Ruane does the maths and explains how he's trying to generate hundreds of pounds per month in passive income…

Read more »

Investing Articles

Prediction: 2 UK shares that could outperform Rolls-Royce between now and 2030

Away from the FTSE 100 and the FTSE 250, Stephen Wright thinks there are some UK shares with outstanding growth…

Read more »

Investing Articles

Can easyJet soar like the Rolls-Royce share price?

Harvey Jones is looking for FTSE 100 stocks that can match the success of the Rolls-Royce share price. Budget carrier…

Read more »

Investing Articles

Is there any growth potential left in Tesla stock?

Tesla stock has shot up 85% in less than three months. Christopher Ruane shares his take on the firm's valuation…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Can Taylor Wimpey rocket like the IAG share price?

The IAG share price smashed the FTSE 100 last year but Harvey Jones thinks it may struggle to repeat that…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Here’s how a stock market beginner could get going in 2025 with £260!

Christopher Ruane explains how a stock market novice could start buying shares for the first time this year with just…

Read more »